SCHEMBL9839672

SCHEMBL9839672

C1=Nc2ncncc2OC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9380796 0.68
SCHEMBL6432328 0.68
SCHEMBL6784491 0.60
SCHEMBL13019057 0.60
SCHEMBL2671182 0.60 ITGB2 (0.33)
SCHEMBL4741894 0.59
SCHEMBL19644130 0.58
SCHEMBL29765349 0.56
SCHEMBL23460361 0.52
SCHEMBL218741 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0228094-B1 Pyrimido[5,4-b][1,4]oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido[5,4-b][1,4]oxazine derivatives CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1991-08-14 EP claimed
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
US-20250163049-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS EXELIXIS INC (US) 2025-05-22 US disclosed
US-20240317775-A1 H4 Antagonist Compounds NXERA PHARMA UK LIMITED (GB) 2024-09-26 US disclosed
EP-4396191-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2024-07-10 EP disclosed
US-20240092779-A1 USP1 INHIBITORS AND USES THEREOF ZENTAUR THERAPEUTICS USA INC. 2024-03-21 US disclosed
WO-2023033740-A9 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2023-12-28 WO disclosed
WO-2023033740-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2023-03-09 WO disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
WO-2022214053-A1 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR 海南耀臻生物医药科技有限公司 2022-10-13 WO disclosed
EP-0228094-B1 Pyrimido[5,4-b][1,4]oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido[5,4-b][1,4]oxazine derivatives CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1991-08-14 EP disclosed
US-4748175-A Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions containing them CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) 1988-05-31 US disclosed
US-4748175-A Pyrimido[5,4-B][1,4]oxazine derivatives and pharmaceutical compositions containing them CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) 1988-05-31 US disclosed
EP-0228094-A2 Pyrimido[5,4-b][1,4]oxazine derivatives, process for their preparation, medicament containing them and intermediate pyrimido[5,4-b][1,4]oxazine derivatives CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1987-07-08 EP disclosed